ICON announced that it has been selected by Roche as its technology partner for storing and managing medical images collected during the company’s clinical research programs.
Roche is using ICON’s MIRA (Medical Image Review and Analysis) software as the company’s central repository for medical images. MIRA is the core application used by ICON Medical Imaging in its daily operations and provides functionality for imaging and clinical data management, image analysis, project management and document management. MIRA is being implemented by Roche in a Software as a Service (SaaS) model, which provides Roche with 24/7 access to imaging data from anywhere in the world and also eliminates the technology costs associated with purchasing and maintaining an image management system in-house. ICON is the first medical imaging provider to offer clients a SaaS solution for their image management needs.
Commenting on the partnership, Dr. Gudrun Zahlman, Leader Imaging Infrastructure at Roche, commented, “We committed to ICON and MIRA after a one year pilot program. The comprehensive functionality of MIRA, the US and EU redundancy of the data, and the responsive nature of the ICON staff, proved the best fit for Roche’s needs. Additionally, we have achieved the seamless integration of images hosted in MIRA with Roche’s clinical data repository and data mining tools for trial decision making, and have integrated 3rd party image analysis software within MIRA for quantitative biomarker research.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.